49 related articles for article (PubMed ID: 9218012)
1. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
[TBL] [Abstract][Full Text] [Related]
2. Machine-learning Algorithm-based Risk Prediction and Screening-detected Prostate Cancer in A Benign Prostate Hyperplasia Cohort.
Chang CC; Chiou JK; Lin CJ; Lu K; Li JR; Chang LW; Hung SC; Cheng CL
Anticancer Res; 2024 Apr; 44(4):1683-1693. PubMed ID: 38537959
[TBL] [Abstract][Full Text] [Related]
3. Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.
Yahya MS; Abdel Hameed FF; Radwan NH; Abdelgawad IA; Soliman AF
Asian Pac J Cancer Prev; 2024 Feb; 25(2):709-717. PubMed ID: 38415559
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
5. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Stapff MP; Palm S
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091398
[No Abstract] [Full Text] [Related]
6. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
Garnick MB
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091399
[No Abstract] [Full Text] [Related]
7. More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
Goodman PJ; Tangen CM; Thompson IM
N Engl J Med; 2019 May; 380(20):e38. PubMed ID: 31091400
[No Abstract] [Full Text] [Related]
8. Finasteride and prostate cancer.
Khan MA; Partin AW
Rev Urol; 2004; 6(2):97-8. PubMed ID: 16985587
[No Abstract] [Full Text] [Related]
9. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting.
Kench JG; Judge M; Delahunt B; Humphrey PA; Kristiansen G; Oxley J; Rasiah K; Takahashi H; Trpkov K; Varma M; Wheeler TM; Zhou M; Srigley JR; Egevad L
Virchows Arch; 2019 Sep; 475(3):263-277. PubMed ID: 31098802
[TBL] [Abstract][Full Text] [Related]
10. Androgenetic Alopecia: An Update of Treatment Options.
Kelly Y; Blanco A; Tosti A
Drugs; 2016 Sep; 76(14):1349-64. PubMed ID: 27554257
[TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes.
Zeigler-Johnson CM; Spangler E; Jalloh M; Gueye SM; Rennert H; Rebbeck TR
Can J Urol; 2008 Feb; 15(1):3872-82. PubMed ID: 18304397
[TBL] [Abstract][Full Text] [Related]
12. The potential for prostate cancer chemoprevention.
Brawley OW
Rev Urol; 2002; 4 Suppl 5(Suppl 5):S11-7. PubMed ID: 16986061
[TBL] [Abstract][Full Text] [Related]
13. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.
Wilde MI; Goa KL
Drugs; 1999 Apr; 57(4):557-81. PubMed ID: 10235693
[TBL] [Abstract][Full Text] [Related]
14. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
Ekman P
Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
[TBL] [Abstract][Full Text] [Related]
15. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
16. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1998 Apr; 51(4A Suppl):58-63. PubMed ID: 9586598
[TBL] [Abstract][Full Text] [Related]
17. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
18. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
